RUBYnanomed was founded in 2018 as a spin-off of INL and aims to bring lab discoveries to the clinical market. RUBYnanomed focusses on non-invasive monitoring of cancer progression through liquid biopsy. Cancer is a major cause of morbidity and mortality worldwide (9.6 million deaths in 2018), but 90 % of those deaths are due to cancer spreading or metastasis.
RUBYnanomed has developed the RUBYchip™, a microfluidic device for fast isolation of circulating tumour cells (CTCs), the cells responsible for metastasis, from unprocessed whole blood samples. Through the analysis of these cells, RUBYnanomed offers a non-invasive and real-time snapshot of cancer progression to oncologists.
Visit their website to learn more: https://www.rubynanomed.com/
For questions or comments, please email us at info@inam.berlin. Also, if you or someone you know would like to be a guest on our show, we welcome any and all suggestions!